Bristol Myers, 2seventy bio halt enrollment in Abecma late-stage trial
(TSVT) stock lost as company with Bristol Myers Squibb (BMY) plan to discontinue enrollments in a Phase 3 trial for cancer ...
2seventy, Bristol Myers Drop Abecma Study in Newly Diagnosed Patients
2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma.
Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting
An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...
BioSpace2d
Schizophrenia Space Anticipates First-in-Class FDA Approval for BMS’ KarXT
With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...
bovnews2d
Bristol-Myers Squibb Co (BMY) Stock Rated Equal Weight by Barclays
On Monday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.01 which represents a slight increase of $0.60 or 1.21% from the prior close of $49.41. The stock opened at ...
BioPharma Dive4d
Novo sinks on obesity drug results; Sanofi reveals anticipated MS data
A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Bristol Myers Squibb Co. closed $10.05 below its 52-week high ($59.46), which the company reached on September 22nd.
Armed robbery in Revesby6d
$6.8M Grant Boosts Replication of KY Lung Cancer Success
A groundbreaking lung cancer screening project co-led by the University of Kentucky Markey Cancer Center and the University of Colorado (CU) Cancer ...
Le Lézard7d
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
Bristol Myers Squibb today announced new data from the Phase 3 DAYBREAK trial demonstrating that decreased rates of brain volume loss were sustained in the open-label extension (OLE) for patients ...
precisionmedicineonline9d
Bristol Myers Squibb's Krazati Bests Chemo in KRAS-Mutant NSCLC With Brain Metastases
Experts noted, however, there is insufficient evidence to determine which commercially available KRAS G12C inhibitor is the ...
Nasdaq15d
September 2025 Options Now Available For Bristol Myers Squibb (BMY)
Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options begin trading today, for the September 2025 expiration. One of the key data points that goes into the price an option buyer is ...